Major advances in the development of oral anticoagulants have resulted in considerable progress towards the goal of safe and effective oral anticoagulants that do not require frequent monitoring or dose adjustment, and have minimal food/drug interactions as highlighted recently in several reports [1-7] and summarized in recent reviews in Cardiovascular Therapeutics and other journals [1-4]. Indirect inhibitors of factor Xa and factor Ila such as low-molecular weight heparin (LMWH) and the pentasaccharide fon-daparinux represent improvements over traditional drugs, such as unfractionated heparin, for acute treatment of VTE, constituting a more targeted anticoagulant approach, with predictable pharma-cokinetic profiles, and no requirement for monitoring [6,7].
展开▼
